SLC12A2 and epilepsy: Among bumetanide derivatives, bumepamine exhibits substantially improved CNS exposure (approximately sevenfold higher than bumetanide) and robust anticonvulsant effects in preclinical rat models of drug-resistant epilepsy, although it does not clearly inhibit NKCC1 [150].